VivoPower will procure Ripple Labs shares for the joint venture’s dedicated investment vehicle, resulting in budgeted management and performance fees for VivoPower of $75 million over 3 years Lean Ventures is a licensed South Korean asset manager which manages funds for the Government of South Korea and other limited partners VivoPower has received approval from Ripple for the purchase of an initial tranche of Ripple Labs shares LONDON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ: ...

Core Insights - ServiceTitan celebrates the second annual Day of the Trades, emphasizing the vital role tradespeople play in the economy and their communities [1][2] - The initiative, Power the Nation, showcases the philanthropic efforts of contractors and trades businesses across the country [1][4] Company Initiatives - True Pros, a residential HVAC and plumbing provider, partnered with ServiceTitan and Make-A-Wish Utah to grant wishes for children, demonstrating a commitment to community support [2][3] - Above + Beyond, an HVAC company, collaborated with ServiceTitan and the Oklahoma Humane Society to enhance conditions for animals, reflecting the company's dedication to community service [3][4] - The Day of the Trades program, launched in 2024, is part of the broader Power the Nation initiative, which encourages tradespeople to leverage their skills for positive community impact [4][5] Future Developments - ServiceTitan is launching the Future of the Trades, an online resource aimed at inspiring the next generation of contractors by highlighting financial opportunities and providing access to training and certifications [6] - This initiative supports workforce development and aims to advance careers in the trades [6] Company Overview - ServiceTitan is a software platform designed to empower trades businesses with an integrated SaaS solution, enabling contractors to manage operations and enhance customer experiences [7]

Strategic partnership with global hospitality platform provider active across 26 countries positions company for significant international hotel market expansionSUNNYVALE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced it has received its first customer order for deployment of its GigaLine hospitality solution. The order i ...

Core Viewpoint - CHAR Technologies Ltd. has successfully closed the order book for a non-brokered private placement, raising a total of $1 million CAD through the issuance of 5,000,000 units at a price of $0.20 CAD per unit [1][2]. Group 1: Offering Details - The Offering has been fully subscribed with participation from institutional investors, and the closing is anticipated by the end of the week of December 16, 2025, subject to necessary approvals [2]. - Each unit consists of one common share and one non-transferable common share purchase warrant, with each warrant exercisable at $0.30 CAD for a period of 24 months from the closing date [3]. - The Company may pay a cash commission of up to 6% of the gross proceeds to certain eligible finders, in compliance with TSXV policies [3]. Group 2: Use of Proceeds - Proceeds from the Offering will be allocated for general working capital, ongoing project development, and capital advisory and investor relations services [4]. Group 3: Company Overview - CHAR Technologies Ltd. specializes in high temperature pyrolysis (HTP) technology, converting unmerchantable wood and organic waste into renewable energy sources, including renewable natural gas and green hydrogen, along with a solid biocarbon product [7]. - The HTP technology aligns with global green energy initiatives by diverting waste from landfills and generating sustainable energy to decarbonize heavy industry [8].

Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for a higher dose of Wegovy (semaglutide 7.2 mg), which could provide individuals with obesity in the EU a new option for significant weight loss, demonstrating an average weight loss of 20.7% at 72 weeks [1][7]. Summary by Sections Clinical Trial Results - The positive opinion is based on the STEP UP and STEP UP T2D clinical trial programs, showing that one in three participants treated with Wegovy achieved 25% or more weight loss at 72 weeks [2][3]. - In the STEP UP trial, 1,407 adults with a BMI ≥30 kg/m² without diabetes participated, confirming the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo [5]. - The majority (84%) of the weight lost with Wegovy was from fat mass, with preserved muscle function [2][5]. Health Benefits - Wegovy has proven health benefits in obesity, including significant reductions in the risk of cardiovascular events such as heart attack and stroke, and alleviation of pain from knee osteoarthritis [1][8]. - The new higher dose aims to enhance weight loss while maintaining the established cardiovascular health benefits of Wegovy [7]. Regulatory and Market Implications - The new Wegovy option could be available early in the new year, pending final approval from the European Commission [3]. - Novo Nordisk has also applied for a single-dose device to deliver Wegovy 7.2 mg and is seeking approval in the US, UK, and other countries [3][9].

Core Insights - LOBO Technologies Ltd. has integrated the entire team of Shenzhen Xiangri Technology Co., Ltd. into its subsidiary Jiangsu LOBO, establishing a new Solar Division to enhance its entry into the photovoltaic energy-storage market [1][4] Company Overview - LOBO Technologies Ltd. specializes in electric mobility and smart energy solutions, manufacturing a variety of eco-friendly electric vehicles and home robotic products [5] - The company aims to promote sustainable transportation options that reduce carbon footprints and enhance energy efficiency [5] Team and Expertise - The Shenzhen Xiangri team, founded in 2012, brings over twelve years of experience in the solar PV industry, focusing on manufacturing solar modules and integrated system solutions [2] - The team holds 15 registered patents related to module fabrication processes and system design, covering product development, sales, and installation services [2] Strategic Collaboration - Shenzhen Xiangri has previously collaborated with Jiangsu LOBO, providing energy solutions for solar-powered electric vehicles, which has led to improved performance metrics [3] - Internal testing indicates that the latest PV-storage-charging integrated solution from Shenzhen Xiangri may enhance the range of low-speed electric vehicles by up to 19% [3] Market Opportunities - The African solar market presents significant opportunities for LOBO's solar-storage solutions, necessitating an experienced technical and sales team for successful project execution [3] - LOBO projects that the newly established Solar Division could generate approximately US$5 million in revenue in 2026, depending on market conditions [4] Industry Growth - The global PV-storage industry is experiencing rapid growth, and LOBO's management believes that integrated PV-storage products offer substantial market opportunities [4] - By leveraging Shenzhen Xiangri's technical expertise and market experience, LOBO aims to accelerate its development in energy storage and become a leading provider of integrated PV-storage solutions [4]

Core Insights - EdgeMode, Inc. has announced the results of an internal review regarding legacy agreements and provided updates on its AI Data Center development in Spain [1] Internal Review of Legacy Agreements - The company identified issues in a share exchange agreement completed earlier this year and intends to pursue rescission based on newly discovered information [2] - The potential impact of this rescission represents less than 5.5% of the company's total AI data center development portfolio, which is currently 1.8 GW of gross capacity in Spain [3] Anti-Dilutive Effects of Pending Rescission Actions - The Board has terminated approximately 385 million unexercised stock options, eliminating 12.8% of potential dilution immediately [4] - If rescission is completed, the company expects to return up to 1.56 billion shares previously issued under the agreement to treasury [4] - These actions could collectively eliminate over 50% of potential and outstanding dilution, significantly increasing shareholder ownership percentage [5] Spain AI Data Center Development Portfolio Continues to Advance - The strategic AI Data Center portfolio in Spain, with a 1.5 GW IT development capacity, remains intact and is progressing on schedule [6] - The company anticipates announcing multiple milestones related to permitting approvals, power procurement, design and engineering updates, and early-stage client engagements in the coming quarters [6] Governance Measures to Support Stability - To ensure continuity during the transition, the company has established a Series D preferred class of stock to provide governance stability, which has no economic dilution effect on common stockholders [6] CEO Comment - The CEO stated that the steps taken strengthen the capital structure and allow the company to focus on advancing its AI Data Center development pipeline in Spain, positioning the company securely for future growth [7]

Group 1 - The company is hosting a Capital Markets Day on 12 May 2026, inviting institutional investors and analysts to attend [1] - The event will be a hybrid format, featuring live streaming and a recording available on the investor website post-event [1] - Limited seats are available for physical attendance at the event location in Hedehusene, Denmark [1] Group 2 - Contact information for investor relations is provided, including the name and contact details of the IR Coordinator [2]

Core Insights - Amplia Therapeutics Limited has reported an additional confirmed partial response in the ongoing ACCENT trial for metastatic pancreatic cancer, indicating progress in their clinical research [1][6] - The confirmed objective response rate (ORR) has reached 35% (19 out of 55 patients), which is significantly higher than the 23% ORR observed in the benchmark MPACT trial for gemcitabine and nab-paclitaxel alone [2][5] Company Overview - Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing a pipeline of Focal Adhesion Kinase (FAK) inhibitors targeting cancer and fibrosis, particularly in fibrotic cancers like pancreatic and ovarian cancer [4] - The company is advancing its lead candidate, narmafotinib, which is a potent and selective FAK inhibitor, currently being tested in the ACCENT trial in combination with gemcitabine and Abraxane for advanced pancreatic cancer [5] Clinical Trial Details - The ACCENT trial has achieved its primary endpoint with a confirmed response rate of 35%, surpassing the benchmark of 23% from the MPACT study [5] - An interim median progression-free survival (PFS) of 7.6 months has also been reported in the trial [5] - A second trial, AMPLICITY, is underway, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients [5]

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III ...